Mass spectrometry based multi-attribute method (MAM) has been commonly proposed to be implemented as a quality control (QC) method for monitoring product critical quality attributes (CQA) of biotherapeutics. Different from characterization methods, regulatory requirements should be followed for developing a QC method for release and stability testing. However, there are some method specific issues for MAM as an advanced technology, for example the additional considerations for method validation and new peak detection feature based on the intended use. Because the ultimate implementation goal of MAM is to replace and consolidate several conventional methods, such as Cation Exchange Chromatography (CEX) for the control of charge variants and Hydrophilic Interaction Chromatography (HILIC) for the control of glycan variants, additional regulatory considerations should also be addressed before its final implementation, for example the comparison between MAM and conventional methods and product specific risk assessment. In this presentation, major regulatory points-to-consider and relevant data expectation to support MAM implementation will be discussed with several case studies along with strategies of rolling in MAM at an appropriate stage during product development.
Some of them have been optimized for certain antibodies in particular. Typically, pre-formulation of Abs starts at these sets of buffers, followed by further improving the conditions of a few selected buffers thereafter. However, to our knowledge, there is no study that has assessed the effect of these buffer formulations on the relative amounts of the antibody modifications (i.e., glycosylation, oxidation and others). Here we present a multiple attribute methodology (MAM) workflow on intact proteins upon reconstruction of data (intact MAM) using liquid chromatography coupled to high resolution mass spectrometry (LC-MS). For this study the effects of 96 commercially available buffer formulations were assessed focusing on the relative abundances of endogenous modifications of the Trastuzumab and our inhouse antibody 17b. For the evaluation, an LC-MS method and data processing workflow for intact MAM were established. Results are presented for a time course study of 7 days of storage at multiple temperatures determining the effect of the different formulations with the optimized method enabling the throughput needed.